Cocrystal Pharma, Inc. (COCP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 2.5M 5M 7.5M Q4 '19: 6.6M Q1 '20: 1.9M Q2 '20: 1.9M Q3 '20: 1.9M Q4 '20: 2M Q4 '19 Q1 '20 Q2 '20 Q3 '20 Q4 '20

Gross Profit TTM

0 3M 6M 9M Q4 '10: 6.8M Q1 '11: 6.3M Q2 '11: 5.5M Q3 '11: 5.5M Q4 '12: 7.4M Q1 '13: 6.6M Q2 '13: 5.1M Q3 '13: 4.3M Q4 '10 Q1 '11 Q2 '11 Q3 '11 Q4 '12 Q1 '13 Q2 '13 Q3 '13

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '16: -55.8M Q4 '16: -105.8M Q1 '17: -103.6M Q2 '17: -101.5M Q3 '17: -101.7M Q4 '17: -9.2M Q1 '18: -8.1M Q2 '18: -8.1M Q3 '18: -8.4M Q4 '18: -62.9M Q1 '19: -58M Q2 '19: -57.4M Q3 '19: -56.8M Q4 '19: -48.4M Q1 '20: -53.2M Q2 '20: -55.1M Q3 '20: -56M Q4 '20: -9.6M Q1 '21: -10.4M Q2 '21: -10.7M Q3 '21: -12M Q4 '21: -14.2M Q1 '22: -15.7M Q2 '22: -36.3M Q3 '22: -38M Q4 '22: -38.8M Q1 '23: -39.7M Q2 '23: -19.6M Q3 '23: -18.4M Q4 '23: -18.6M Q1 '24: -17.6M Q2 '24: -18.7M Q3 '24: -19.3M Q4 '24: -17.9M Q1 '25: -16.1M Q2 '25: -12.7M Q3 '25: -9.8M Q4 '25: -9M Q1 '26: -9M Q2 '26: -10.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q3 '16: -39.6M Q4 '16: -74.9M Q1 '17: -73.4M Q2 '17: -72.4M Q3 '17: -72.8M Q4 '17: -2.2M Q1 '18: -1.2M Q2 '18: -257K Q3 '18: 135K Q4 '18: -49M Q1 '19: -44.5M Q2 '19: -44.7M Q3 '19: -44.6M Q4 '19: -48.2M Q1 '20: -53.1M Q2 '20: -55.1M Q3 '20: -56M Q4 '20: -9.6M Q1 '21: -10.4M Q2 '21: -10.7M Q3 '21: -12M Q4 '21: -14.2M Q1 '22: -15.7M Q2 '22: -36.3M Q3 '22: -38M Q4 '22: -38.8M Q1 '23: -39.8M Q2 '23: -19.6M Q3 '23: -18M Q4 '23: -18M Q1 '24: -16.8M Q2 '24: -17.9M Q3 '24: -18.7M Q4 '24: -17.5M Q1 '25: -15.8M Q2 '25: -12.6M Q3 '25: -9.7M Q4 '25: -8.8M Q1 '26: -8.8M Q2 '26: -9.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q3 '16: -15.3M Q4 '16: -14.6M Q1 '17: -12.6M Q2 '17: -8.6M Q3 '17: -7.6M Q4 '17: -6.9M Q1 '18: -6.9M Q2 '18: -7.9M Q3 '18: -7.9M Q4 '18: -8.3M Q1 '19: -4.2M Q2 '19: -3.1M Q3 '19: -2.3M Q4 '19: -1.6M Q1 '20: -5.8M Q2 '20: -6.9M Q3 '20: -8.7M Q4 '20: -9.8M Q1 '21: -9.4M Q2 '21: -9.8M Q3 '21: -12.2M Q4 '21: -12.7M Q1 '22: -14.9M Q2 '22: -16M Q3 '22: -19.5M Q4 '22: -21.4M Q1 '23: -20.6M Q2 '23: -22.5M Q3 '23: -16.2M Q4 '23: -14.7M Q1 '24: -16.1M Q2 '24: -14.2M Q3 '24: -16.7M Q4 '24: -16.5M Q1 '25: -14.9M Q2 '25: -13.4M Q3 '25: -9.6M Q4 '25: -8.2M Q1 '26: -7.6M Q2 '26: -8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q4 '11: -996.4K Q1 '12: -2.7M Q2 '12: -2.5M Q3 '12: -2.8M Q4 '13: -3.7M Q3 '15: -9.2M Q4 '15: -10.7M Q1 '16: -13.2M Q2 '16: -15.7M Q3 '16: -15.5M Q4 '16: -14.6M Q1 '17: -12.7M Q2 '17: -8.6M Q3 '17: -7.7M Q4 '17: -6.9M Q1 '18: -6.9M Q2 '18: -7.9M Q3 '18: -7.9M Q4 '18: -8.3M Q1 '19: -4.2M Q2 '19: -3.2M Q3 '19: -2.5M Q4 '19: -1.7M Q1 '20: -6M Q2 '20: -7.3M Q3 '20: -8.9M Q4 '20: -10.1M Q1 '21: -9.6M Q2 '21: -9.9M Q3 '21: -12.2M Q4 '21: -12.8M Q3 '23: -16.3M Q4 '23: -14.8M Q1 '24: -16.1M Q2 '24: -14.3M Q3 '24: -16.7M Q4 '24: -16.5M Q1 '12 Q4 '15 Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q3 '23 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 250M 500M 750M Q1 '13: 57.3K Q2 '13: 57.3K Q3 '13: 70.1M Q1 '14: 324.5K Q2 '14: 326.8K Q3 '14: 327.2K Q1 '15: 439.9K Q2 '15: 696.8K Q3 '15: 696.9K Q1 '16: 697.3M Q2 '16: 705.6M Q3 '16: 707.5M Q1 '17: 23.8M Q2 '17: 24.3M Q3 '17: 728M Q1 '18: 24.4M Q2 '18: 27.7M Q3 '18: 29.9M Q1 '19: 30.4M Q2 '19: 31.6M Q3 '19: 31.6M Q1 '20: 41.7M Q2 '20: 52.1M Q1 '21: 71.3M Q2 '21: 87.1M Q3 '21: 8.1M Q1 '22: 8.1M Q2 '22: 8.1M Q3 '22: 8.1M Q1 '23: 8.1M Q2 '23: 10.1M Q3 '23: 10.2M Q1 '24: 10.2M Q2 '24: 10.2M Q3 '24: 10.2M Q1 '25: 10.2M Q2 '25: 10.2M Q3 '25: 11M Q1 '26: 13.8M Q2 '26: 13.8M Q2 '14 Q1 '16 Q3 '17 Q2 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q1 '12: -0.15 Q2 '12: -0.15 Q3 '12: -0.11 Q4 '12: -0.13 Q3 '16: -0.06 Q4 '16: -3.07 Q1 '17: -3.17 Q2 '17: -3.26 Q3 '17: -3.26 Q4 '17: 0.00 Q1 '18: 0.05 Q2 '18: 0.09 Q3 '18: 0.03 Q4 '18: -1.75 Q1 '19: -1.59 Q2 '19: -1.59 Q3 '19: -1.59 Q4 '19: -1.51 Q1 '20: -1.66 Q2 '20: -1.68 Q3 '20: -1.67 Q4 '20: -0.18 Q1 '21: -0.17 Q2 '21: -0.14 Q3 '22: -4.26 Q4 '22: -4.76 Q1 '23: -4.88 Q2 '23: -2.29 Q3 '23: -2.00 Q4 '23: -1.90 Q1 '24: -1.65 Q2 '24: -1.77 Q3 '24: -1.85 Q4 '24: -1.73 Q1 '25: -1.57 Q2 '25: -1.24 Q3 '25: -0.94 Q4 '25: -0.79 Q1 '26: -0.73 Q2 '26: -0.76 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.